1700632927
1700632928
[23] Recker R, Stakkestad JA, Chesnut CH III，et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal postmenopausal osteoporosis. Bone, 2004, 34
:890-899.
1700632929
1700632930
[24] Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone, 2004, 34
:881-889.
1700632931
1700632932
[25] Solomon Epstein, MD. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Solomon Epstein. clinical therapeutics, 2006, 28
:151-173
1700632933
1700632934
[26] Rosen CJ, Hochberg MC, Bonnick SL, et al. For the fosamax actonel comparison trial investigators. treatment with once-weekly Mendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized doubleblind study. J Bone Miner Res, 2005, 20
:141-151.
1700632935
1700632936
[27] Eastell R, Delmas PD. How to interpret surrogate markers of efficacy in osteoporosis. J Bone Miner Res, 2005, 20
:1261-1262.
1700632937
1700632938
[28] Guyatt GH, Cranney A, Griffith L, et al. Summary of meta-anatyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin Nortk Am, 2002, 31
:659-679.
1700632939
1700632940
[29] Lindsay R, Magowan S, Miller P, et al. Treatment-related changes in BMD are not associated with the occurrence of a fragility fracture while on risedronate therapy. Poster presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research, 2005, 9
:23-27.
1700632941
1700632942
[30] Cauley JA, Black DM, Barrett-Conner E, et al. For the HERS Research Group. Effects of hormone replacement therapy on clinical fractures and height loss: The heart and estrogen/progestin replacement study. Am J Med, 2001, 110
:442-450.
1700632943
1700632944
[31] Hulley S, Furberg C, Barrett-Connor E, et al. For the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up（HERS Ⅱ). JAMA, 2002, 288
:58-66.
1700632945
1700632946
[32] Heinemann DF. Osteoporosis. An overview of the national osteoporosis foundation clinical practice guide. Geriatrics, 2000, 55
:31-36.
1700632947
1700632948
[33] Bryant HU. Mechanism of actionand preclinical profile of raloxifene: A selective estrogen receptor modulator. Rev Endocr Metab Disord. 2001, 2
:129-138.
1700632949
1700632950
[34] Ettinger B, Black DM, Mitlak BH, et al. For the multiple outcomes of raloxifene evaluation（MORE）Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999, 282
:637-645.
1700632951
1700632952
[35] Delmas PD, Ensrud KE, Adachi JD, et al. For the multiple outcomes of raloxifene evaluation investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from arandomized clinical trial. J Clin Endocrinol Metab. 2002, 87
:3609-3617.
1700632953
1700632954
[36] Kelminski A. The study of tamoxifen and raloxifene（STAR trial）for the prevention of breast cancer. Hawaii Med J, 2002, 61
:209-210.
1700632955
1700632956
[37] Brown Jp, Josse RG. For the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. published corrections appear in CMAJ, 2003, 168
:400.
1700632957
1700632958
[38] Gompel A, Jacob D, de Chambine S, et al. Action of SERM and SAS（tibolone）on breast tissue. Contracept Fertil Sex. 1999, 27
:368-375.
1700632959
1700632960
[39] Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003, 362
:419-427.
1700632961
1700632962
[40] Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ. 1992, 305
:556-561.
1700632963
1700632964
[41] Chesnut CH III，Silverman S, Andriano K, et al. for the PROOF study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med, 2000, 109
:267-276.
1700632965
1700632966
[42] Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Solomon Epstein Clinical Therapeutics, 2006, 28
:151-173.
1700632967
1700632968
[43] Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology, 1932, 16
:547-558.
1700632969
1700632970
[44] Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res, 1989, 4
:283-291.
1700632971
1700632972
[45] Rubin MR, Cosman F, Lindsay R, et al. The anabolic effects of parathyroid hormone. Osteoporos Int, 2002, 13
:267-277.
1700632973
1700632974
[46] Juppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science, 1991, 254
:1024-1026.
1700632975
1700632976
[47] Canalis E, Centrella M, Burch W, et al. Insulin-like growth factor Ⅰ mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest, 1989, 83
:60-65.
[
上一页 ]
[ :1.700632927e+09 ]
[
下一页 ]